Imatinib Unknown Status Phase 2 Trials for Chronic Myeloid Leukemia (CML)

IndicationsStatusPurposePhase
Unknown StatusNot Available2
clinicaltrials.gov IdentifierTitleDrugs
NCT00146913AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year